Myomo, Inc.
BST:0M61 Stok Raporu
Myomo Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 0/6 Myomo şirketinin temettü ödeme geçmişi bulunmamaktadır.
Anahtar bilgiler Toplam Hissedar Getirisi -5.2% Gelecekteki Temettü Verimi n/a Temettü Büyümesi n/a Bir sonraki temettü ödeme tarihi n/a Eski temettü tarihi n/a Hisse başına temettü n/a Ödeme oranı n/a
Son temettü ve geri alım güncellemeleri
Tüm güncellemeleri göster
Third quarter 2024 earnings released: US$0.025 loss per share (vs US$0.058 loss in 3Q 2023) Nov 08 Myomo, Inc. Revises Revenue Guidance for the Year 2024
Myomo, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31
New minor risk - Financial position Aug 07
Second quarter 2024 earnings released: US$0.03 loss per share (vs US$0.036 loss in 2Q 2023) Aug 07
Myomo, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 31
Myomo, Inc. Provides Revenue Guidance for the Second Quarter Ended June 30, 2024 Jul 08
Lead Independent Director recently bought €162k worth of stock Jun 03
Chief Medical Officer recently sold €120k worth of stock May 20
Forecast to breakeven in 2026 May 12
Myomo, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024 May 10
Full year 2023 earnings released: US$0.28 loss per share (vs US$1.52 loss in FY 2022) May 09
New minor risk - Profitability May 09
Myomo, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
Myomo, Inc., Annual General Meeting, Jun 05, 2024 Apr 28
Myomo, Inc. Appoints Heather Getz as Class II Director and Chair of Audit Committee Mar 29
Lead Independent Director recently bought €161k worth of stock Mar 19
Forecast to breakeven in 2026 Mar 09
Myomo, Inc. Provides Earnings Guidance for the First Quarter of 2024 Mar 08
New minor risk - Market cap size Jan 26
Myomo, Inc. to Report Q4, 2023 Results on Mar 15, 2024 Jan 18 Myomo, Inc. has filed a Follow-on Equity Offering in the amount of $6.000002 million.
Forecast to breakeven in 2026 Dec 31
Third quarter 2023 earnings released: US$0.058 loss per share (vs US$0.40 loss in 3Q 2022) Nov 09
Myomo, Inc. Announces CMS Posts Proposed Medicare DMEPOS Fee Schedule Rate for the MyoPro for Review at the Upcoming HCPCS Public Meeting Nov 08
Myomo, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Nov 01
Chairman recently bought €56k worth of stock Sep 01
Second quarter 2023 earnings released: US$0.036 loss per share (vs US$0.42 loss in 2Q 2022) Aug 11
Myomo, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Aug 03
Centers for Medicare and Medicaid Services Accepts Myomo, Inc.'s Application to Classify the MyoPro as A Brace Jul 04
First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.41 loss in 1Q 2022) May 12
Myomo, Inc. Provides Revenue Guidance for the Second Quarter of 2023 May 11
Myomo, Inc. to Report Q1, 2023 Results on May 10, 2023 May 04
Full year 2022 earnings released: US$1.52 loss per share (vs US$1.89 loss in FY 2021) Mar 14
the National Disability Insurance Scheme in Australia Approves Myomo, Inc.'s MyoPro for Patient with Paralyzed Arm Feb 07
Myomo, Inc. Appoints Yitzchak Jacobovitz as A Class II Director Jan 31
Insufficient new directors Jan 01
Third quarter 2022 earnings released: US$0.40 loss per share (vs US$0.36 loss in 3Q 2021) Nov 16
Myomo, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022 and Full Year of 2023 Nov 11
Myomo, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 04
Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.47 loss in 2Q 2021) Aug 05
Myomo, Inc. Provides Revenue Guidance or Third Quarter 2022 Aug 04 Myomo, Inc. Provides Revenue Guidance for the Second Quarter of 202
First quarter 2022 earnings released: US$0.41 loss per share (vs US$0.57 loss in 1Q 2021) May 13
Myomo, Inc. to Report Q1, 2022 Results on May 11, 2022 May 05
Myomo, Inc., Annual General Meeting, Jun 08, 2022 May 02
No longer forecast to breakeven Apr 27
No longer forecast to breakeven Mar 11
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 11
Myomo, Inc. to Report Q4, 2021 Results on Mar 09, 2022 Mar 04
Myomo Announces MyoPro® 2+ Jan 07
Forecast to breakeven in 2024 Jan 01
Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.70 loss in 3Q 2020) Nov 12
Second quarter 2021 earnings released: US$0.47 loss per share (vs US$1.12 loss in 2Q 2020) Aug 12
No longer forecast to breakeven Jun 10
First quarter 2021 earnings released: US$0.57 loss per share (vs US$2.52 loss in 1Q 2020) May 09
Revenue beats expectations Mar 12
Full year 2020 earnings released: US$3.47 loss per share (vs US$19.35 loss in FY 2019) Mar 12
Myomo, Inc. to Report Q4, 2020 Results on Mar 10, 2021 Mar 05
Myomo, Inc. Announces Techniker Krankenkasse Approves Reimbursement of the Company Feb 17
New 90-day high: €12.10 Feb 13
Myomo® Forms Joint Venture to Manufacture and Sell the Company’s Products in China Jan 28
New 90-day high: €9.80 Jan 27
Myomo Inc.'s Sublease with Upstatement, LLC Becomes Effective Jan 21
New 90-day high: €7.50 Jan 12
Myomo, Inc. Introduces MyoGames Nov 17
Revenue beats expectations Nov 12
New 90-day high: €4.64 Nov 12
Third quarter 2020 earnings released: US$0.70 loss per share Nov 12
Myomo, Inc. to Report Q3, 2020 Results on Nov 10, 2020 Nov 05
Myomo, Inc. Appoints Harry Kovelman as Chief Medical Officer Nov 03
New 90-day low - €2.96 Aug 26
Earnings released Aug 11
Myomo, Inc. to Report Q2, 2020 Results on Aug 10, 2020 Aug 06
New 90-day low - €3.02 Jul 30
Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: 0M61 şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.
Büyüyen Temettü: 0M61 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.
Piyasaya Karşı Temettü Getirisi Myomo Piyasaya Karşı Temettü Getirisi
0M61 temettü verimi piyasa ile karşılaştırıldığında nasıldır? Segment Temettü Verimi Şirket (0M61) n/a Pazarın Alt %25'i (DE) 1.7% Pazarın En İyi %25'i (DE) 4.8% Sektör Ortalaması (Medical Equipment) 1.9% Analist tahmini (0M61) (3 yıla kadar) n/a
Önemli Temettü: 0M61 şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.
Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, 0M61 şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: 0M61 şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranı nı hesaplamak üzere yeterli veri yok.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: 0M61 herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.
Güçlü temettü ödeyen şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}